Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure
- 1 February 1986
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 57 (4), 254-259
- https://doi.org/10.1016/0002-9149(86)90901-x
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement.Circulation, 1985
- Selective inhibitors of three forms of cyclic nucleotide phosphodiesterasesTrends in Pharmacological Sciences, 1984
- Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.Circulation, 1984
- Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failureJournal of the American College of Cardiology, 1984
- Evaluation of a New Bipyridine Inotropic Agent — Milrinone — in Patients with Severe Congestive Heart FailureNew England Journal of Medicine, 1983
- The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure.Circulation, 1983
- Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failureThe American Journal of Cardiology, 1983
- Long-term amrinone therapy in patients with severe heart failureAmerican Journal Of Medicine, 1982
- Hemodynamic effects of intravenous prenalterol in severe heart failureThe American Journal of Cardiology, 1981
- Improved radioimmunoassay of platelet factor 4 and β-thromboglobulin in plasmaClinica Chimica Acta; International Journal of Clinical Chemistry, 1980